Form 4: Bicycle Therapeutics Chief Technology Officer Executes Stock Transactions Following RSU Vesting

Michael Skynner, Chief Technology Officer of Bicycle Therapeutics, acquired shares through a restricted stock unit vesting and sold shares to cover tax obligations.

Summary

• Michael Skynner, the Chief Technology Officer of Bicycle Therapeutics, received 35,000 ordinary shares as part of a restricted stock unit (RSU) award on January 2, 2025.
• These RSUs vest over time, with one-fourth vesting on January 2, 2026, and the remainder vesting in equal quarterly installments thereafter.
• To cover tax obligations associated with the vesting, Mr. Skynner sold 3,287 shares on January 2, 2025, at an average price of $14.09 and 936 shares on January 3, 2025, at an average price of $14.75.
• Mr. Skynner also received an option to purchase 87,000 ordinary shares at an exercise price of $14 on January 2, 2025, which vests over time.
• Following these transactions, Mr. Skynner beneficially owns 123,722 ordinary shares.

Sentiment

Score: 7

Explanation: The document reflects routine transactions related to executive compensation. There is no indication of positive or negative sentiment, it is a standard disclosure.

Positives

• The vesting of restricted stock units and the granting of stock options are standard compensation practices that align the interests of management with those of shareholders.
• The transactions are part of a pre-determined plan to cover tax obligations, which is a common practice.

Risks

• The sale of shares by an executive, even for tax purposes, could be perceived negatively by some investors, although this is a standard practice.
• The vesting schedule of the RSUs and options could create future selling pressure if the executive chooses to sell shares as they vest.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Industry Context

This is a standard SEC Form 4 filing, which is a routine disclosure for company insiders who have transacted in the company's stock. It is common for executives to receive stock-based compensation and to sell shares to cover tax obligations.

Comparison to Industry Standards

• The vesting schedule of the RSUs and stock options is typical for executive compensation packages in the biotechnology industry.
• The 'sell to cover' transaction for tax obligations is a common practice among publicly traded companies.
• The reported share prices are within the expected range for a company in the biotechnology sector.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are routine and related to executive compensation.
• The sale of shares to cover tax obligations is a standard practice and should not significantly affect the share price.

Next Steps

• The remaining RSUs will vest in 12 equal quarterly installments after January 2, 2026.
• The stock options will vest in 36 equal monthly installments after January 2, 2026.

Key Dates

Keywords

stock options, restricted stock units, insider trading, share transactions, executive compensation, Bicycle Therapeutics, BCYC